Friday, 9 October 2015

Is EAE Dead?

The good news that anti-CD20 is affecting relapsing and progressive MS is going to mean a rethink.

Anti-CD20 inhibits many suspected autoimmunities. Is it by depleting a CD20+ T cell, blocking antigen presenting function or by killing the reservoir of the autoimmune virus that leads to MS.

The concept of autoimmunity has been led by T cell immunologists, and some have B cells and antibodies at their core despite being driven by T cells.

Personally I think that anti-CD20 is pretty rubbish in EAE, as this is a T cell-mediated disease and the effects of B cell depletion is marginal.

Rituximab was good at inhibiting EAE in human CD20-transgenic mice, it was also killing T cells as well as B cells in the mice. 

However, we will now see EAE become a B cell-mediated disease.
Copaxone will get another mechanism of action:-)...but it is potentially an antigen presentation blocker anyway

At TeamG, we left the focus of T cells many years ago, although recently we have been there and EAE can be used to model damage and disease control irrespective of whether it is T cell mediated or not...however is this another nail in the coffin?

2 comments:

  1. At least now maybe the mice "suffer" for a purpose "more concrete" as the B cells seem to have much influence on disease cells T ... Many EAE studies "shooting everywhere" ...

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.